Repeated hsCRP may predict mortality risk among patients of acute HF
High-sensitivity C-reactive protein (hsCRP) has long been recognized as a marker of inflammation in various medical contexts. Among patients hospitalized for heart failure, elevated hsCRP levels at admission have been associated with worse outcomes. However, a recent study delves deeper into the long-term cumulative effects of hsCRP levels on the prognosis of heart failure patients.
The study results were published in the Journal of the American Heart Association.
The study enrolled a total of 1281 patients who were hospitalized for heart failure. These patients were monitored at admission and at 1 and 12 months after discharge to collect hsCRP data. The researchers employed two approaches to assess long-term cumulative hsCRP levels: quartiles of cumulative hsCRP levels and cumulative instances of high hsCRP levels. Patients were categorized into four groups based on these criteria.
A total of 1281 patients with a median age was 64 (interquartile range, 54–73) years were included. Of these 35.4% were women.During a follow-up period averaging 4.8 years, 374 (29.2%) patients passed away. The study found a compelling link between elevated long-term cumulative hsCRP levels and increased mortality risk.
Findings:
- When compared to quartile 1 (used as a reference), the hazard ratios (HRs) for mortality were 1.29 (95% CI, 0.92–1.81) for quartile 2, 1.62 (95% CI, 1.16–2.25) for quartile 3, and 2.38 (95% CI, 1.75–3.23) for quartile 4 demonstrating a progressively higher mortality risk with increasing quartiles of cumulative hsCRP levels.
- Likewise, patients were grouped based on the cumulative times their hsCRP levels exceeded cutoff values.
- When compared to patients with 0-times (hsCRP levels below cutoff values in all three time points), those with 1-time had an HR of 1.36 (95% CI, 0.92–2.01), those with 2-times had an HR of 1.95 (95% CI, 1.34–2.82), and those with 3-times had an HR of 2.80 (95% CI, 1.97–4.00) which suggests a substantial increase in mortality risk with each additional instance of high hsCRP levels.
Thus, the study's findings underscore the significance of long-term cumulative hsCRP levels in predicting outcomes for patients hospitalized for acute heart failure. Monitoring hsCRP levels over time could assist physicians in identifying patients at a higher risk of mortality. Early identification and intervention for patients with elevated long-term hsCRP levels may offer a valuable tool in improving their prognosis and overall care.
Further reading: Long‐Term Cumulative High‐Sensitivity C‐Reactive Protein and Mortality Among Patients With Acute Heart Failure. https://doi.org/10.1161/JAHA.123.029386, Journal of the American Heart Association. 2023;12:e029386.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.